This is an example of the Medis Medical Imaging Quantitative Flow Ratio (QFR) system that offers a fractional flow...
TCT
This channel contains news about the annual Transcatheter Cardiovascular Therapeutics (TCT) conference presented by the Cardiovascular Research Foundation (CRF). It includes coverage from the annual meeting and links CRF news. TCT is the premier conference for the subspecialty of interventional cardiology, including the new subspecialty areas of transcatheter structural heart procedures.
-
-
This is an example of the Siemens Corindus CorPath Cath lab robotic system being used for a percutaneous coronary intervention (PCI) stent implant simulation on the expo floor at the 2019...
-
December 1, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC) magazine website from the month of November 2020.
-
Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials presented at the 2020...
Videos | FFR Technologies | December 16, 2020
This is an example of the Medis Medical Imaging Quantitative Flow Ratio (QFR) system that offers a fractional flow...
Videos | Robotic Systems | December 16, 2020
This is an example of the Siemens Corindus CorPath Cath lab robotic system being used for a percutaneous coronary...
COVID-19 cardiology related content continues to be among the top performers on the DAIC website in November 2020. TAVR also topped headlines with Boston Scientific taking its Lotus valve off the market and a review of TAVR registry data showing it is now the dominant method of aortic valve replacement in the United States.
Feature | Cardiovascular Business | December 01, 2020 | Dave Fornell, Editor
December 1, 2020 — Here is the list of the most popular content on the Diagnostic and Interventional Cardiology (DAIC)...
Figure 1: PROTECT III found, when compared to intra-aortic balloon pump (IABP), Impella use led to a 29% reduction in MACCE at 90 days.
News | Hemodynamic Support Devices | November 12, 2020
November 12, 2020 — Abiomed recently announced new PROTECT III study data that demonstrates reduced rates of MACCE (...
Some of the device technologies discussed in the TCT 2020 late-breaking trial sessions. Top left, the Medtronic Resolute Onyx stent was the first stent to receive FDA clearance for short duration dual-antiplatelet therapy, which was a big topic and subject of several sessions. Lower left, the Keystone TriGuard 3 TAVR embolic protection device did not demonstrate superiority over TAVR without use of embolic protection. Top right, the Abbott MitraClip was the subject of two studies, including use to aid heart transplant patients. Bottom right, the Boston Scientific Acurate neo TAVR valve performed below the Sapien 3 and CoreValve Evolut.
Feature | TCT | October 29, 2020 | Dave Fornell, Editor
Here are some of the key takeaways from the late-breaking interventional cardiology and structural heart trials...
Patient case example of the FlowTriever thrombectomy device from Inari Medical Inc. in removing a pulmonary embolism and reporting blood flow and clot burden removed by the system.
News | Pulmonary Embolism | October 23, 2020
October 23, 2020 — Positive results were reported on the first 230 patients enrolled in its FLASH study, a real world...
FFR assessment of a coronary lesion using the Philips Healthcare Volcano FFR system.
News | FFR Technologies | October 23, 2020
October 23, 2020 – A new observational study of deferred lesions following combined fractional flow reserve (FFR) and...
News | FFR Technologies | October 23, 2020
October 23, 2020 – Results from the randomized controlled TARGET FFR trial show that while a physiology-guided...
An example of a HeartFlow FFR-CT image showing the blood flow through what looked like a significant blockage on CT angiography alone, actually was not flow-limiting based on computational fluid dynamics. Use of the technology was supposed to reduce the number of diagnostic catheterizations in the FORECAST trial, but the costs of FFR-CT were not offset enough to show cost savings.
News | FFR Technologies | October 22, 2020 | Dave Fornell, Editor
October 22, 2020 – In the FORECAST randomized clinical trial, the use of fractional flow reserve (FFR) derived from...
Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates.
Feature | Stents | October 22, 2020 | Dave Fornell, Editor
October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durable...
News | Stents | October 22, 2020
October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnology...
Videos | Hemodynamic Support Devices | October 20, 2020
Chuck Simonton, M.D., chief medical officer at Abiomed, discusses some of the new technologies and clinical trials the...
Videos | Cath Lab | October 19, 2020
Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ...
Videos | Stents Drug Eluting | October 19, 2020
Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ...
Videos | Antiplatelet and Anticoagulation Therapies | October 19, 2020
The COMPARE CRUSH Trial looked at the effect of pre-hospital crushed prasugrel tablets in patients with STEMI planned...
